Tianjin Lifeon Pharmaceutical Co., Ltd.
According to the "Administrative Measures for Independent Directors of Listed Companies" and the "Independent Director System of Tianjin Lifeon Pharmaceutical Co., Ltd." (hereinafter referred to as the "Company"), I, as an independent director of Tianjin Lifeon Pharmaceutical Co., Ltd., hereby submit my annual performance report to the Board of Directors and Shareholders, explaining the fulfillment of my duties. Your review is requested.
I. Basic Information (I) Work Experience, Professional Background, and Concurrent Positions My name is Zhang Mei. I hold a Ph.D. in Management with a major in Accounting and possess the title of Senior Accountant. I am a certified public accountant, asset appraiser, and tax advisor in China. I previously served as a certified public accountant, chief accountant, and director at Tianjin Xinhua Certified Public Accountants Firm. Currently, I am the director and chief accountant of Tianjin Xinhua Certified Public Accountants Firm and an independent director of Tianjin Sai Xiang Technology Co., Ltd. I have served as an independent director of the Company since December 2020. I meet the qualifications for an independent director of a listed company as stipulated by relevant laws, regulations, and regulatory rules, and have been filed and reviewed by the Shenzhen Stock Exchange.
(II) No Circumstances Affecting Independence I do not hold any positions in the Company other than that of director. I have no direct or indirect interest in the Company or its major shareholders, nor any other relationship that could affect my independent and objective judgment. I fulfill my duties independently, free from the influence of the Company, its major shareholders, or any other entity or individual. In 2025, I conducted a self-assessment of my independence and confirmed that I meet all applicable regulatory requirements.
The independence requirements for serving as an independent director of the Company have been met, and my self-assessment results have been submitted to the Board of Directors. The Board of Directors has evaluated my independence and found no circumstances that could affect my independent and objective judgment, concluding that I continue to maintain my independence as an independent director.
II. Attendance at Meetings In 2025, the Company held a total of 8 Board of Directors meetings, of which 2 were held in person. There were 5 Shareholders' meetings and 3 Independent Director special committee meetings. I attended all Company Board meetings, Shareholders' meetings, and Independent Director special committee meetings on time. I did not have any absences or miss two consecutive Board meetings without personal attendance. This year, I carefully reviewed all proposals submitted to the Board of Directors, Shareholders' meetings, and Independent Director special committee meetings. I maintained full communication with the Company's management, offered some constructive suggestions, and exercised my voting rights with a prudent attitude. I believe that the convening and holding of the Company's Board and Shareholders' meetings complied with legal procedures, and major operational matters underwent the necessary approval procedures, making them legal and valid. Therefore, I voted in favor of all proposals and other matters at the Company's Board and Independent Director special committee meetings in 2025, with no dissenting opinions, objections, or abstentions.
III. Issuance of Independent Opinions In 2025, as an independent director, I provided prior approval for and issued opinions on significant matters of the Company, actively participating in communication and supervision of the regular report audit work, leveraging my professional expertise as an independent director. During the reporting period, I issued independent opinions on the following matters of the Company:
- Proposal on adjusting matters related to the 2024 Restricted Stock Incentive Plan
- Proposal on the first grant of restricted shares to the incentive recipients of the 2024 Restricted Stock Incentive Plan (II) On March 19, 2025, at the 50th meeting of the Seventh Board of Directors, I issued independent opinions on the following matters:
- Special explanation regarding the Company's cumulative and current external guarantees and fund occupation.